Format

Send to

Choose Destination
See comment in PubMed Commons below
Vet Comp Oncol. 2009 Mar;7(1):38-44. doi: 10.1111/j.1476-5829.2008.00170.x.

Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.

Author information

1
Comparative Oncology Program, Department of Small Animal Medicine and Surgery, University of Georgia, College of Veterinary Medicine, Athens, GA 30602, USA. northrup@uga.edu

Abstract

Forty-one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21-day cycle, shortened from the 28-day MOPP cycle). The overall response rate to MPP was 34% for a median of 56 days (95% confidence interval 30-238). Seventeen percent of dogs had a complete response for a median duration of 238 days, 17% had a partial response for a median of 56 days and 32% had stable disease for a median of 24 days. Histological grade or cell morphology on cytology was associated with response. Minimal toxicity was observed with the MPP protocol, suggesting that further dose intensification or addition of another chemotherapeutic agent would be possible.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center